Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

fibrodysplasia ossificans progressiva

Screenshot of the first page of the PLSP article.
22nd Sep 2025

A plain language summary of the LUMINA-1 study: bone imaging in patients with fibrodysplasia ossificans progressiva

his is a plain language summary of a clinical research study called LUMINA-1. This study investigated a medicine called garetosmab in adults with fibrodysplasia ossificans progressiva, or FOP. FOP is a very rare disease that causes new bone to form in places where it does not usually develop (also known as heterotopic ossification). In FOP, when bone is formed in areas it is not supposed to, it results in mature heterotopic bone. The build-up of new bone makes it difficult for people with FOP to move, which means they often require the use of a wheelchair or other mobility aid. People with FOP who took part in the study were experiencing bone formation in areas where new bone should not form, flare-ups (episodes of localized swelling, pain, and/or warmth), and worsening joint movement
30th Apr 2024

LUMINA-1 study: A plain language summary looking at the effects of garetosmab in people with fibrodysplasia ossificans progressiva (FOP)

1st Mar 2023

The effects of palovarotene in patients with fibrodysplasia ossificans progressiva: a plain language summary

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy